Corrigendum: Biomarkers of Response to Ocrelizumab in Relapsing-Remitting Multiple Sclerosis

This is a corrigendum (correction notice) for a peer-reviewed study investigating biomarkers that predict treatment response to ocrelizumab in patients with relapsing-remitting multiple sclerosis. The notice addresses corrections to the original published article.